November 23, 2015November 23, 2015

PTC Therapeutics’ CF Therapy in 2nd Fully Enrolled Phase 3 Trial

Cystic Fibrosis, News

PTC Therapeutics announced that it has completed patient enrollment in its second Phase 3 clinical trial, known as ACT CF, to evaluate Translarna™ (ataluren) as treatment for patients with nonsense mutation cystic fibrosis ... Read more

October 6, 2015November 5, 2015

EMA Validates PTC Therapeutics’ Submission for New Nonsense Mutation Cystic Fibrosis Indication for Translarna (Ataluren)

Cystic Fibrosis, News

The European Medicines Agency (EMA) recently accepted a submission of variation for a new indication from PTC Therapeutics regarding Translarna (ataluren) for nonsense mutation cystic fibrosis (nmCF), which would allow the drug ... Read more